相关实验视频
Updated: Jan 21, 2026

07:42
A Data-Driven Approach to Quantifying Immune States in Sepsis
Published on: February 7, 2025
483
直接进入第三阶段:以模型为基础的方法加快了depemokimab在因特鲁金-5驱动疾病中的临床发展
Chiara Zecchin1, Stein Schalkwijk2, Isabelle J Pouliquen3
1Clinical Pharmacology Modelling and Simulation, GSK, Stevenage, UK.
Clinical pharmacology and therapeutics
|January 20, 2026
概括
基于模型的药物开发 (MIDD) 和定量决策 (QDM) 加快了depemokimab的发展速度.
科学领域:
- 药量计和临床药理学.
- 生物药物和治疗开发.
- 炎症性疾病研究的研究.
背景情况:
- 干白素-5 (IL-5) 在严重喘,CRSwNP,EGPA和HES中驱动2型炎症.
- 血中乙氨基酸细胞数 (BEC) 的减少是抗IL-5生物疗效的关键生物标志物.
- 德佩莫基马布是一种超长效应的抗IL-5生物疗法.
研究的目的:
- 利用基于模型的药物开发 (MIDD) 和定量决策 (QDM) 来优化德佩莫基马布的临床开发.
- 根据BEC减少,预测严重喘,CRSwNP,EGPA和HES的有效depemokimab剂量.
- 评估MIDD/QDM在加速depemokimab向III期试验的进展方面的效率.
主要方法:
- 开发了贝叶斯的非线性混合效应剂量-时间响应模型,以预测德佩莫基马布剂量对与梅波利祖马布可比的BEC减少.
- 采用量化决策 (QDM) 采用预先指定的去/不去标准来评估成功概率.
- 进行了IIb期试验模拟,使用负二项式分布用于年化恶化率和PK/PD (BEC) 模型用于III期剂量预测.
主要成果:
- 单次使用depemokimab剂量≥60mg显示≥80%的概率超过了在III期试验中观察到的最低BEC减少目标.
- 临床试验模拟表明<3%的概率改善了与传统剂量范围研究的III期剂量精度.
- 选择的德佩莫基马布剂量:在严重喘/CRSwNP时100毫克,在EGPA/HES时200毫克,在III期每26周.
结论:
- MIDD和QDM成功预测了最佳的DepemokimabIII期剂量,实现了目标的BEC减少.
- MIDD/QDM方法显著缩短了depemokimab开发时间表的2-3年.
- 该战略强调了将新疗法从第一阶段直接推向第三阶段的潜力,从而优化药物开发效率.
相关概念视频
Coronary Artery Disease III: Clinical Manifestations
332
Coronary Artery Disease (CAD) is a primary health risk worldwide, leading to significant morbidity and mortality. The condition arises from the buildup of atherosclerotic plaques within the coronary arteries, resulting in diminished blood supply to the heart muscle.The clinical manifestations of CAD vary widely, from asymptomatic stages to severe, life-threatening conditions. Understanding these manifestations is crucial for early diagnosis and effective management.Angina Pectoris: The Warning...
332
Peptic Ulcer Disease III: Clinical Manifestations and Diagnostic Studies
546
Peptic ulcer disease (PUD) presents with diverse symptoms depending on the location and severity of the ulcer. Clinical manifestations of peptic ulcer include dull pain and a burning sensation in the mid-epigastric region.
Few clinical manifestations differentiate gastric ulcers from duodenal ulcers. Distinctions in the location, timing, and pain relief are crucial for healthcare providers in differentiating between gastric and duodenal ulcers during clinical assessments.
Few clinical manifestations differentiate gastric ulcers from duodenal ulcers. Distinctions in the location, timing, and pain relief are crucial for healthcare providers in differentiating between gastric and duodenal ulcers during clinical assessments.
546
ATP Driven Pumps III: V-type Pumps
4.7K
V-type pumps are ATP-driven pumps found in the vacuolar membranes of plants, yeast, endosomal and lysosomal membranes of animal cells, plasma membranes of a few specialized eukaryotic cells, and some prokaryotes. They are also known as the V1Vo-ATPase, that couple ATP hydrolysis to transport protons against a concentration gradient.
The peripheral or cytosolic V1 domain with eight subunits is involved in ATP hydrolysis. The integral or transmembrane V0 domain containing at least five subunits...
The peripheral or cytosolic V1 domain with eight subunits is involved in ATP hydrolysis. The integral or transmembrane V0 domain containing at least five subunits...
4.7K
Gastritis III: Clinical Manifestations and Management
1.2K
The clinical manifestations of gastritis can vary depending on the cause and type of gastritis, but some common symptoms may include the following.
Clinical manifestations of acute gastritis
The patient with acute gastritis may have a rapid onset of symptoms, such as epigastric pain or discomfort, dyspepsia, anorexia, hiccups, or nausea and vomiting, which can last from a few hours to a few days. Erosive or hemorrhagic gastritis may cause bleeding, which may manifest as blood in vomit or as...
Clinical manifestations of acute gastritis
The patient with acute gastritis may have a rapid onset of symptoms, such as epigastric pain or discomfort, dyspepsia, anorexia, hiccups, or nausea and vomiting, which can last from a few hours to a few days. Erosive or hemorrhagic gastritis may cause bleeding, which may manifest as blood in vomit or as...
1.2K
Heart Failure III: Clinical Manifestations
516
Heart failure (HF) manifests primarily as dyspnea, fatigue, and fluid retention, resulting in peripheral and pulmonary edema. Symptoms may vary depending on which ventricle is more affected, left or right.Left-Sided Heart FailureAlso known as left ventricular failure, this condition results from the left ventricle's inability to fill or eject sufficient blood into the systemic circulation. It leads to pulmonary congestion, which occurs when the left ventricle fails to eject blood effectively...
516
Angina III: Clinical Manifestations and Assessment
205
Angina manifests as chest pain, tightness, or squeezing discomfort typically located behind the breastbone. It can radiate to the neck, jaw, shoulders, and inner aspects of the upper arms, most commonly the left arm. Patients may experience shortness of breath, fatigue, profuse sweating, dizziness, indigestion, heartburn, palpitations, anxiety, and vomiting as accompanying symptoms. This pain often lasts a few minutes and is triggered by physical exertion, emotional stress, heavy meals, or cold...
205

